- Home
- EVGN vs IMRN Comparison
EVGN vs IMRN Comparison
Compare EVGN & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVGN
- IMRN
- Stock Information
- Founded
- EVGN 1999
- IMRN 1994
- Country
- EVGN Israel
- IMRN Australia
- Employees
- EVGN N/A
- IMRN N/A
- Industry
- EVGN Agricultural Chemicals
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- EVGN Industrials
- IMRN Health Care
- Exchange
- EVGN Nasdaq
- IMRN Nasdaq
- Market Cap
- EVGN 9.7M
- IMRN 9.2M
- IPO Year
- EVGN N/A
- IMRN N/A
- Fundamental
- Price
- EVGN $1.09
- IMRN $1.77
- Analyst Decision
- EVGN Strong Buy
- IMRN Strong Buy
- Analyst Count
- EVGN 1
- IMRN 1
- Target Price
- EVGN $3.50
- IMRN $5.00
- AVG Volume (30 Days)
- EVGN 47.1K
- IMRN 49.4K
- Earning Date
- EVGN 05-21-2025
- IMRN 06-10-2025
- Dividend Yield
- EVGN N/A
- IMRN N/A
- EPS Growth
- EVGN N/A
- IMRN N/A
- EPS
- EVGN N/A
- IMRN N/A
- Revenue
- EVGN $6,765,000.00
- IMRN $4,048,286.00
- Revenue This Year
- EVGN $68.62
- IMRN N/A
- Revenue Next Year
- EVGN $66.92
- IMRN N/A
- P/E Ratio
- EVGN N/A
- IMRN N/A
- Revenue Growth
- EVGN N/A
- IMRN 82.90
- 52 Week Low
- EVGN $0.95
- IMRN $1.50
- 52 Week High
- EVGN $7.75
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- EVGN 40.78
- IMRN 47.77
- Support Level
- EVGN $1.08
- IMRN $1.75
- Resistance Level
- EVGN $1.43
- IMRN $1.92
- Average True Range (ATR)
- EVGN 0.08
- IMRN 0.19
- MACD
- EVGN -0.01
- IMRN 0.00
- Stochastic Oscillator
- EVGN 8.11
- IMRN 43.00
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.